West Pharmaceutical Services, Inc. (WST)
NYSE:WST
Want to see WST full AI Analyst Report?
WST Stock Chart & Stats
$273.73
$0.15(0.05%)
At close: 4:00 PM EST
$273.73
$0.15(0.05%)
Day’s Range― - ―
52-Week Range$206.80 - $330.88
Previous CloseN/A
Volume102.64K
Average Volume (3M)902.70K
Market Cap
$22.35B
Enterprise Value$22.60B
Total Cash (Recent Filing)$521.40M
Total Debt (Recent Filing)$316.20M
Price to Earnings (P/E)42.1
Beta0.80
Next Earnings
Jul 23, 2026EPS Estimate
2.08Next Dividend Ex-DateN/A
Dividend Yield0.32%
Share Statistics
EPS (TTM)7.52
Shares Outstanding70,647,600
10 Day Avg. Volume718,132
30 Day Avg. Volume902,703
Financial Highlights & Ratios
PEG Ratio34.00
Price to Book (P/B)6.26
Price to Sales (P/S)6.47
P/FCF Ratio42.42
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue7.02
Enterprise Value/Gross Profit19.37
Enterprise Value/Ebitda28.29
Forecast
1Y Price Target
$355.00Price Target Upside29.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)8.62
Revenue Forecast (FY)$3.33B
Bulls Say, Bears Say
Bulls Say
Balance Sheet HealthVery low leverage and a sizeable equity base provide durable financial flexibility. This conservatism supports continued capex for capacity, execution of the $1B buyback, M&A optionality, and resilience to input-cost or timing shocks without jeopardizing investment in growth or qualification programs.
High-Value Products & GLP-1 ExposureHVP components and GLP-1 exposure anchor durable, above-market demand. High-value, proprietary components create sticky qualification cycles and higher margins; secular GLP-1, biologics, and delivery-device trends structurally expand addressable volumes and mix toward premium products.
Cash GenerationConsistent OCF and meaningful FCF underpin funding for R&D, capacity builds and shareholder returns without reliance on new debt. Operating cash exceeds net income, signaling earnings quality and allowing sustained reinvestment and capital allocation even as FCF conversion shows some variability.
Bears Say
Contract Concentration / CGM Roll-OffDependence on large contracts creates durable revenue sensitivity; the CGM exit illustrates how single-contract roll-offs can dent growth and compress near-term visibility. Replacing volumes requires customer qualification and time, leaving top-line volatility until new wins scale.
Ramp-Related Margin VariabilityNew site ramping and facility startups can persistently depress segment margins until utilization and efficiency are achieved. With site qualification lead times of ~6–12 months, incremental capacity adds may initially dilute margins and delay expected operating leverage benefits.
Working Capital & FCF ConversionModerate FCF conversion and AR-driven OCF weakness reduce near-term cash flexibility. Working-capital sensitivity to sales cadence and bonus payouts can limit the pace of buybacks or extra reinvestment and introduces recurring cash-timing risk that may constrain strategic optionality.
West Pharmaceutical Services News
WST FAQ
What was West Pharmaceutical Services, Inc.’s price range in the past 12 months?
West Pharmaceutical Services, Inc. lowest stock price was $206.80 and its highest was $330.88 in the past 12 months.
What is West Pharmaceutical Services, Inc.’s market cap?
West Pharmaceutical Services, Inc.’s market cap is $22.35B.
When is West Pharmaceutical Services, Inc.’s upcoming earnings report date?
West Pharmaceutical Services, Inc.’s upcoming earnings report date is Jul 23, 2026 which is in 47 days.
How were West Pharmaceutical Services, Inc.’s earnings last quarter?
West Pharmaceutical Services, Inc. released its earnings results on Apr 23, 2026. The company reported $2.13 earnings per share for the quarter, beating the consensus estimate of $1.678 by $0.452.
Is West Pharmaceutical Services, Inc. overvalued?
According to Wall Street analysts West Pharmaceutical Services, Inc.’s price is currently Undervalued.
Does West Pharmaceutical Services, Inc. pay dividends?
West Pharmaceutical Services, Inc. pays a Quarterly dividend of $0.22 which represents an annual dividend yield of 0.32%. See more information on West Pharmaceutical Services, Inc. dividends here
What is West Pharmaceutical Services, Inc.’s EPS estimate?
West Pharmaceutical Services, Inc.’s EPS estimate is 2.08.
How many shares outstanding does West Pharmaceutical Services, Inc. have?
West Pharmaceutical Services, Inc. has 70,647,600 shares outstanding.
What happened to West Pharmaceutical Services, Inc.’s price movement after its last earnings report?
West Pharmaceutical Services, Inc. reported an EPS of $2.13 in its last earnings report, beating expectations of $1.678. Following the earnings report the stock price went up 12.86%.
Which hedge fund is a major shareholder of West Pharmaceutical Services, Inc.?
Currently, no hedge funds are holding shares in WST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
West Pharmaceutical Services Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$355.00 (29.69% Upside)
$355.00 (29.69% Upside)
Blogger Sentiment
Bullish
WST Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 925.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.57%
12-Months-Change
Fundamentals
Return on Equity
17.87%
Trailing 12-Months
Asset Growth
13.59%
Trailing 12-Months
Company Description
West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
WST Company Deck
WST Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reported broad-based, above-expectation Q1 results with strong revenue growth, substantial margin expansion and raised full-year guidance. Key growth engines—HVP components (including GLP-1s), biologics/NovaPure, Annex 1 conversions, and delivery devices—showed robust performance and underpin optimism. Near-term headwinds include a ~$40M CGM contract roll-off in H2, AR-driven cash flow timing effects, ramp-related margin variability and some commodity cost pressure, but management has mitigation plans and a strong balance sheet (including a new $1B buyback). Overall, positive operational execution and upgraded guidance outweigh the manageable challenges.View all WST earnings summariesWST Revenue Breakdown
81.07% Proprietary Products
18.93% Contract-Manufactured Products
0.00% Intersegment sales elimination
WST Stock 12 Month Forecast
Average Price Target
$355.00
▲(29.69% Upside)
Technical Analysis
Ownership Overview
0.55% Insiders
26.54% Mutual Funds
30.30% Other Institutional Investors
12.62% Public Companies and
Individual Investors